Ogivri Kit
Product Images NDC 83257-004

10 FDA label images from Biocon Biologics Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Ogivri (NDC 83257-004). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Biocon Biologics Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 9 Ogivri For Injection 420 mg/vial Carton Label (Image 9)

Figure 9 Ogivri For Injection 420 mg/vial Carton Label (Image 9)
Packaging label for Ogivri (trastuzumab-dkst) injection, powder, lyophilized for solution, 420 mg per vial. The label shows the product as a multiple-dose vial for intravenous infusion after reconstitution. The manufacturer is Biocon Biologics Inc. The label includes storage instructions to keep refrigerated and specifies no preservative.*
FDA Label Image

Figure 1 (Figure 01)

Figure 1 (Figure 01)
A cumulative incidence plot showing the time from initiation of Paclitaxel/Trastuzumab treatment over a period of approximately 9 years. The chart compares two groups labeled AC -> T and AC -> T+H, with corresponding cumulative incidence curves and shaded confidence intervals. The table below the x-axis displays the number of patients at risk at various time points for each group.*
FDA Label Image

Figure 2 (Figure 02)

Figure 2 (Figure 02)
A cumulative incidence plot comparing trastuzumab 1-year treatment with observation only over 24 months from randomization. The x-axis shows time in months, the y-axis shows cumulative incidence. The chart includes the number at risk for each group at regular intervals, with trastuzumab represented by a solid line and observation only by a dashed line.*
FDA Label Image

Figure 3 (Figure 03)

Figure 3 (Figure 03)
A line graph depicting cumulative incidence over time (months) for three chemotherapy regimens: AC->T (doxorubicin + cyclophosphamide followed by docetaxel), AC->TH (doxorubicin + cyclophosphamide followed by docetaxel + trastuzumab), and TCH (docetaxel + carboplatin + trastuzumab). The x-axis represents time in months up to 36, and the y-axis shows cumulative incidence from 0.00 to 0.50. The graph includes a risk table showing the number of patients at risk for each regimen at intervals up to 36 months.*
FDA Label Image

Figure 4 (Figure 04)

Figure 4 (Figure 04)
A Kaplan-Meier survival curve showing disease-free survival over time in years, with proportion event-free on the y-axis. The graph compares two treatment groups: AC followed by TH (doxorubicin + cyclophosphamide followed by paclitaxel + trastuzumab) and AC followed by T (doxorubicin + cyclophosphamide followed by paclitaxel). The graph also includes a table listing the number of patients at risk at various time points for each group.*
FDA Label Image

Figure 5 (Figure 05)

Figure 5 (Figure 05)
This is a survival curve chart comparing overall survival (in years) and proportion alive between two treatment groups: AC->T (doxorubicin + cyclophosphamide followed by paclitaxel) and AC->T + (the same regimen with added trastuzumab). The chart shows the proportion alive decreasing over time for both groups, with the trastuzumab group generally showing higher survival. The number at risk at various time points is displayed below the x-axis.*
FDA Label Image

Figure 6 (Figure 06)

Figure 6 (Figure 06)
A Kaplan-Meier survival curve graph showing disease-free survival over approximately 5 years. The graph compares three treatment regimens: AC -> TH (doxorubicin + cyclophosphamide followed by docetaxel + trastuzumab), TCH (docetaxel + carboplatin + trastuzumab), and AC -> T (doxorubicin + cyclophosphamide followed by docetaxel). The y-axis represents the proportion event-free, and the x-axis represents years of disease-free survival. Number at risk at different time points is also displayed.*
FDA Label Image

Figure 7 (Figure 07)

Figure 7 (Figure 07)
A Kaplan-Meier survival curve chart titled 'Product-Limit Survival Estimates' showing survival probability over duration of survival in months. Two groups are compared: one receiving Fluoropyrimidine + Cisplatin (solid line), and the other Fluoropyrimidine + Cisplatin + Trastuzumab (dashed line). The chart includes number of subjects at risk at various time points and indicates censored data points with plus symbols.*
FDA Label Image

Carton-420mg (Carton 420mg)

Carton-420mg (Carton 420mg)
Ogivri 420 mg/vial (trastuzumab-dkst) injection, powder, lyophilized for solution. The label shows that this product is for intravenous use, multiple-dose vial, and requires refrigeration. It is labeled for prescription use only and marketed by Biocon Biologics Inc. The carton includes storage instructions and a barcode.*
FDA Label Image

Carton-150 (Carton 150)

Carton-150 (Carton 150)
Label for OGIVRI 150 mg/vial (trastuzumab-dkst) injection, lyophilized powder for solution for intravenous infusion. The label indicates it is a single-dose vial with no preservative, to be refrigerated, and unused portions discarded. Manufactured by Biocon Biologics Inc., the label includes dosing instructions and storage information along with the NDC 83257-001-11 and barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.